Fuan Pharmaceutical (Group) Balance Sheet Health
Financial Health criteria checks 5/6
Fuan Pharmaceutical (Group) has a total shareholder equity of CN¥4.3B and total debt of CN¥716.0M, which brings its debt-to-equity ratio to 16.6%. Its total assets and total liabilities are CN¥6.0B and CN¥1.7B respectively. Fuan Pharmaceutical (Group)'s EBIT is CN¥258.1M making its interest coverage ratio -3. It has cash and short-term investments of CN¥953.7M.
Key information
16.6%
Debt to equity ratio
CN¥716.03m
Debt
| Interest coverage ratio | -3x |
| Cash | CN¥953.73m |
| Equity | CN¥4.32b |
| Total liabilities | CN¥1.68b |
| Total assets | CN¥6.00b |
Recent financial health updates
Recent updates
There's No Escaping Fuan Pharmaceutical (Group) Co., Ltd.'s (SZSE:300194) Muted Earnings
Aug 23
Does Fuan Pharmaceutical (Group) (SZSE:300194) Have A Healthy Balance Sheet?
Jun 07Fuan Pharmaceutical (Group)'s (SZSE:300194) Shareholders May Want To Dig Deeper Than Statutory Profit
May 02Insufficient Growth At Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Hampers Share Price
Apr 03Financial Position Analysis
Short Term Liabilities: 300194's short term assets (CN¥2.2B) exceed its short term liabilities (CN¥1.4B).
Long Term Liabilities: 300194's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥322.4M).
Debt to Equity History and Analysis
Debt Level: 300194 has more cash than its total debt.
Reducing Debt: 300194's debt to equity ratio has increased from 1% to 16.6% over the past 5 years.
Debt Coverage: 300194's debt is well covered by operating cash flow (73.6%).
Interest Coverage: 300194 earns more interest than it pays, so coverage of interest payments is not a concern.